This inventor holds 7 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignees: Korea Atomic Energy Research Institute, Korea Research Institute of Chemical Technology, Korea Pharma Co., Ltd.. Active years: 1992-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Daejun, KR (1992)
- Daejeon-si, KR (2007)
- Seoul, KR (2020)
- Daejeon, KR (2005 - 2021)
Company Filing History:
4 out of 428 
2 out of 654 
1 out of 2 
Years Active: 1992-2025
Title: Byung Chul Shin: Innovator in Cancer Treatment and Drug Delivery
Introduction
Byung Chul Shin is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the fields of cancer treatment and drug delivery systems. With a total of 7 patents, his work focuses on innovative solutions that address critical health challenges.
Latest Patents
One of his latest patents is the "Anti-TM4SF4 antibody and uses thereof." This invention relates to novel antibodies or antigen-binding fragments that specifically bind to TransMembrane 4 Superfamily Member 4 (TM4SF4). These antibodies exhibit proliferation inhibitory activity against cancer cells, effectively preventing or treating cancer. They also reduce the self-renewal ability of cancer stem cells, making them useful in treating cancers with poor prognoses in conventional anticancer treatments.
Another significant patent is the "Microspherical sustained-release injection containing escitalopram and method for preparing same." This invention involves a biodegradable polymer microsphere-containing sustained-release injection with escitalopram as the active ingredient. The patent addresses challenges such as low encapsulation rates and initial over-release by maximizing encapsulation efficiency and controlling the release dynamics of the microspheres.
Career Highlights
Byung Chul Shin has worked with notable institutions, including the Korea Atomic Energy Research Institute and the Korea Research Institute of Chemical Technology. His experience in these organizations has contributed to his expertise in developing innovative medical solutions.
Collaborations
Some of his coworkers include Sang Hyun Park and Kyung Bae Park. Their collaborative efforts have likely enhanced the research and development of his patented technologies.
Conclusion
Byung Chul Shin's innovative work in cancer treatment and drug delivery systems showcases his commitment to advancing medical science. His patents reflect a deep understanding of the challenges in these fields and offer promising solutions for future therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile